Effects of long-term antihypertensive therapy on physical fitness of men with mild hypertension. 1997

H Tomiyama, and N Doba, and T Kushiro, and M Yamashita, and H Yoshida, and K Kanmatsuse, and N Kajiwara, and S Hinohara
Third Department of Internal Medicine, Teikyo University School of Medicine, Ichihara, Japan.

This study was conducted to investigate the effects of long-term administration of a calcium-channel antagonist (nifedipine) and a beta-blocker (acebutolol) on physical fitness in men with mild hypertension. All subjects underwent symptom-limited treadmill stress testing and routine echocardiographic studies. Twenty-two subjects who had either a causal diastolic blood pressure of more than 105 mmHg or a left ventricular mass index (LVMI) of 125 g/m2 or more during follow-up were assigned to receive medical therapy. The other 31 men who did not meet either criterion were continuously followed-up without medication. Among the 22 treated men, the age-adjusted treadmill time (normalized treadmill time, TMTn) significantly decreased before the initiation of medication, while 31 untreated men showed no change in TMTn throughout the study. The 22 treated subjects were subsequently divided into two groups; 13 were given nifedipine and 9 were given acebutolol. All treated subjects were followed-up for more than 3 years. After treatment, the two groups showed similar reductions in blood pressure and LVMI, but a different outcome for TMTn: TMTn increased from 104 +/- 8% to 115 +/- 16% in subjects given nifedipine (p < 0.05) and decreased from 106 +/- 12% to 99 +/- 10% (p < 0.01) in those given acebutolol. Thus, the physical fitness of subjects who required medication significantly deteriorated without medication; their physical fitness improved after treatment with a calcium-channel antagonist and deteriorated after treatment with a beta-blocker.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D010809 Physical Fitness The ability to carry out daily tasks and perform physical activities in a highly functional state, often as a result of physical conditioning. Fitness, Physical
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004452 Echocardiography Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic. Echocardiography, Contrast,Echocardiography, Cross-Sectional,Echocardiography, M-Mode,Echocardiography, Transthoracic,Echocardiography, Two-Dimensional,Transthoracic Echocardiography,2-D Echocardiography,2D Echocardiography,Contrast Echocardiography,Cross-Sectional Echocardiography,Echocardiography, 2-D,Echocardiography, 2D,M-Mode Echocardiography,Two-Dimensional Echocardiography,2 D Echocardiography,Cross Sectional Echocardiography,Echocardiography, 2 D,Echocardiography, Cross Sectional,Echocardiography, M Mode,Echocardiography, Two Dimensional,M Mode Echocardiography,Two Dimensional Echocardiography

Related Publications

H Tomiyama, and N Doba, and T Kushiro, and M Yamashita, and H Yoshida, and K Kanmatsuse, and N Kajiwara, and S Hinohara
May 1985, Arquivos brasileiros de cardiologia,
H Tomiyama, and N Doba, and T Kushiro, and M Yamashita, and H Yoshida, and K Kanmatsuse, and N Kajiwara, and S Hinohara
January 1985, Acta medica Scandinavica,
H Tomiyama, and N Doba, and T Kushiro, and M Yamashita, and H Yoshida, and K Kanmatsuse, and N Kajiwara, and S Hinohara
December 1987, Journal of clinical pharmacology,
H Tomiyama, and N Doba, and T Kushiro, and M Yamashita, and H Yoshida, and K Kanmatsuse, and N Kajiwara, and S Hinohara
January 1985, Fertility and sterility,
H Tomiyama, and N Doba, and T Kushiro, and M Yamashita, and H Yoshida, and K Kanmatsuse, and N Kajiwara, and S Hinohara
February 1994, Kidney international. Supplement,
H Tomiyama, and N Doba, and T Kushiro, and M Yamashita, and H Yoshida, and K Kanmatsuse, and N Kajiwara, and S Hinohara
September 1983, The American journal of medicine,
H Tomiyama, and N Doba, and T Kushiro, and M Yamashita, and H Yoshida, and K Kanmatsuse, and N Kajiwara, and S Hinohara
January 1997, Hypertension (Dallas, Tex. : 1979),
H Tomiyama, and N Doba, and T Kushiro, and M Yamashita, and H Yoshida, and K Kanmatsuse, and N Kajiwara, and S Hinohara
January 2000, Blood pressure monitoring,
H Tomiyama, and N Doba, and T Kushiro, and M Yamashita, and H Yoshida, and K Kanmatsuse, and N Kajiwara, and S Hinohara
January 1983, Hypertension (Dallas, Tex. : 1979),
H Tomiyama, and N Doba, and T Kushiro, and M Yamashita, and H Yoshida, and K Kanmatsuse, and N Kajiwara, and S Hinohara
August 1982, International journal of clinical pharmacology, therapy, and toxicology,
Copied contents to your clipboard!